In a small study where anti-PD-L1 and anti-PD-1 treatment was administered to cancer patients with systemic sclerosis, 24% of patients experienced flares and almost 60% developed irAEs, with only 6% developing grade 3-4 irAEs (162). Here, PDCD1 is linked to cancer.